Capstone Therapeutics Short Interest Drops 31% in February

Biotech firm sees significant decline in shares shorted amid market volatility.

Mar. 15, 2026 at 1:08pm

Got story updates? Submit your updates here. ›

Capstone Therapeutics Corp. (NASDAQ:CAPS), a biotechnology company based in Tempe, Arizona, saw a 31.1% drop in short interest on its stock during the month of February. As of February 27th, there were 103,151 shares shorted, down from 149,731 shares on February 12th. The short interest ratio is currently 1.1 days, indicating the stock is relatively liquid.

Why it matters

Short interest can be an indicator of investor sentiment and market expectations around a company. The significant decline in short interest for Capstone Therapeutics suggests improved confidence in the stock, potentially driven by positive developments or a shift in the broader market outlook.

The details

Capstone Therapeutics is a biotech firm that develops novel peptides and molecules for underserved medical conditions. The company's lead product candidate, AEM-28, has completed early-stage clinical trials. The drop in short interest comes amid volatility in the broader biotech and healthcare sectors, which have seen increased investor scrutiny.

  • As of February 27th, 2026, Capstone Therapeutics had 103,151 shares shorted.
  • On February 12th, 2026, Capstone Therapeutics had 149,731 shares shorted.

The players

Capstone Therapeutics Corp.

A biotechnology company developing novel peptides and molecules for underserved medical conditions, headquartered in Tempe, Arizona.

DRW Securities LLC

A hedge fund that recently bought a new stake in Capstone Therapeutics, owning 1.51% of the company's shares.

Got photos? Submit your photos here. ›

The takeaway

The significant decline in short interest for Capstone Therapeutics suggests improved investor sentiment and confidence in the company's prospects, despite ongoing volatility in the broader biotech sector. This could signal potential positive developments or a shift in market expectations for the firm's pipeline and future performance.